Last reviewed · How we verify
EP2006
EP2006 is a biosimilar of epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.
EP2006 is a biosimilar of epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia in patients with chronic kidney disease, Chemotherapy-induced anemia in cancer patients.
At a glance
| Generic name | EP2006 |
|---|---|
| Also known as | Filgrastim |
| Sponsor | Sandoz |
| Drug class | Erythropoietin receptor agonist (biosimilar) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
EP2006 is designed as a biosimilar to recombinant human erythropoietin (epoetin alfa), which mimics the natural hormone that regulates red blood cell production. By binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes their proliferation and differentiation, increasing hemoglobin and red blood cell counts. This mechanism is used therapeutically to treat anemia in patients with chronic kidney disease, cancer patients receiving chemotherapy, and other conditions associated with low red blood cell production.
Approved indications
- Anemia in patients with chronic kidney disease
- Chemotherapy-induced anemia in cancer patients
Common side effects
- Hypertension
- Thrombotic events
- Headache
- Injection site reactions
Key clinical trials
- Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (PHASE3)
- Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (PHASE3)
- Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia (PHASE4)
- Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EP2006 CI brief — competitive landscape report
- EP2006 updates RSS · CI watch RSS
- Sandoz portfolio CI